Pulmonary drug delivery strategies: A concise, systematic review

Lung India

Volumn 29, Issue 1, 2012, Pages 44-49

  Patil, J S ^a   Sarasija, S ^b,c  

^a BLDE UNIVERSITY   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Dry powder inhaler; lung deposition; pulmonary route; targeted drug delivery

Indexed keywords

EXCIPIENT;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; EMULSION; FREEZE DRYING; HUMAN; PARTICULATE MATTER; POWDER INHALER; REVIEW; SPRAY DRYING;

EID: 84856619564     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.92361     Document Type: Review

References (49)

1. Groneberg DA, Nickolaus M, Spinger J, Doring F, Daniel H, Fischer A. Localization of peptide transporter PEPT2 in the lung: implications of pulmonary oligopeptide uptake. Am J Pathol 2001;158:707-14. (Pubitemid 32158632)
2. Groneberg DA, Eynott PR, Döring F, Dinh QT, Oates T, Barnes PJ, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fbrosis human lung. Thorax 2002;57:55-60. (Pubitemid 34081545)
3. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Resp Med 2003;97:382-87. (Pubitemid 36410606)
4. Tuncer DI, Nevin C. Controlled Delivery of Peptides and Proteins. Curr Pharm Des 2007;13:99-117.
5. Sangwan S, Agosti JM, Bauer LA, Otulana BA, Morishige RJ, Cipolla DC, et al. Aerozolized protein delivery in asthma: Gamma camera analysis of regional deposition and perfusion. J Aerosol Med 2001;14:185-95. (Pubitemid 32744350)
6. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptide. J Physio Pharmacol 2007;58:615-25. (Pubitemid 351346710)
7. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules:- principles, problems and examples. J Physio Pharmacol 2008;59:53-79.
8. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacother 2002;22:71-9.
9. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006;58:1061-75. (Pubitemid 44780908)
10. Ptton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801. (Pubitemid 39382220)
11. Guntur VP, Dhand R. Inhaled insulin: extending the horizons of inhalation therapy. Respir Care 2007;52:911-22.
12. Codrons, V, Vanderbist F, Verbeeck RK. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003;92:938-50. (Pubitemid 36523439)
13. Gessler T, Schmehl T, Olschewski H, Grimminger F, Seeger W. Aerosolized vasodilators in pulmonary hypertension. J Aerosol Med 2002;15:117-22. (Pubitemid 34827524)
14. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonaryhypertension. J Aerosol Med 2008;21:1-12.
15. Fores B, Ehrhardt C. Human respiratory epithelial cell culture for drug deliveryapplications. Eur J Pharm Biopharm 2005;60:193-205. (Pubitemid 40804561)
16. Evans CM, Koo JAS. Airway mucus: the good, the bad, the sticky. Pharmacol Therapeut 2009;121:332-48.
17. Palecanda A, Kobzik L. Receptors for unopsonized particles: The role of alveolarmacrophages scavenger receptors. Curr Molecul Med 2001;1:589-95. (Pubitemid 33772037)
18. Lizio R, Klenner T, Borchard G, Romeis P, Sarlikiotis AW, Reissmann T, et al. Delivery of the GnRH antagonist centrolix by intratracheal instillation in Anesthetized rats. Eur J Pharm Sci 2000;9:253-8.
19. Chono S, Tanino T, Seki T, Morimoto K. Infuence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofoxacin incorporated into liposomes. J Drug Target 2006;14:557-66. (Pubitemid 44592889)
20. Chan HK. Inhalation drug delivery devices and emerging technologies. Expert Opin Ther Patents 2003;13:1333-43.
21. Geller DE. New liquid aerosol generation devices: System that force pressurized liquids through nozzles. Respir Care 2002;47:1392-404.
22. Geller DE. Thippawong J, Otulana B. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fbrosis. J Aerosol Med 2003;16:175-82. (Pubitemid 36702671)
23. rd. Inhaled insulin using the AERx insulin Diabetes management system in healthy and asthmatic subjects. Diabet Care 2003;26:764-69. (Pubitemid 36929341)
24. Voss AP, Finley WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm 2003;248:39-50.
25. Coates MS, Fletcher DF, Chan HK, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fuid dynamics. Part I: Grid structure and mouthpiece Length Pharm Sci 2004;11:2863-76. (Pubitemid 39506635)
26. Perez-Gil J. Structure of pulmonary surfactant membranes and flms: The role of proteins and lipid-protein interactions. Biochimica et Biophysics Acta 2008;1778:1676-95.
27. Hickey AJ, Garcia-Contreras L. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit Rev Ther Drug Carrier Syst 2001;18:387-431. (Pubitemid 32953900)
28. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabet Care 2000; 23: 1343-47.
29. Mosen K, Backstrom K, Thalberg K. Particle formation and capture during spray drying of inhale particles. Pharm Dev Technol 2004;9:409-18.
30. Duddu SP, Sisk SA, Walter YH. Improved lung delivery from a passive dry powder inhaler using an engineered pulmosphere powder. Pharm Res 2002;19:689-95. (Pubitemid 34553679)
31. White S, Bennett DB, Cheu S. Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005;7:896-906. (Pubitemid 43133996)
32. Gilani K, Najafabad AR, Berge M, Rafee-Tehrani M. The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles J Pharm Sci 2005;94:1048-59. (Pubitemid 40780771)
33. 2 and cryogenic spray-freezing technologies. Drug Dev Ind Pharm 2001;27:1003-16.
34. Maa YF, Prestrelski SJ. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 2000;1:283-302.
35. Yu Z, Garcia AS, Johnston KP, Williams RO. Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles. Eur J Pharm Biopharm 2004;58:529-37. (Pubitemid 39297099)
36. Kuo JH, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: Effects of protective agents on the stability of DNA. J Pharm Pharmacol 2004;56:27-33. (Pubitemid 38195325)
37. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of solid nanoparticle suspensions using supercritical fuid extraction of emulsions for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007;59:444-53. (Pubitemid 47259225)
38. Rehman M, Shekunov BY, York P. Optimization of powders for pulmonary delivery using supercritical fuid technology. Eur J Pharm Sci 2004;22:1-17. (Pubitemid 38543009)
39. Rasenack N, Steckel H, Mullar BW. Micronization of anti-infammatory drugs forpulmonary delivery by a controlled crystallization process. J Pharm Sci 2003;92:35-44. (Pubitemid 36042295)
40. TM nanoparticles. J Control Rel 2007;121:10-8. (Pubitemid 47126067)
41. Gratton SE, Napier ME, Ropp PA, Tian S, DeSimon JM. Microfabricated particles for engineered drug therapies: Elucidation into the mechanisms of cellular internalization of PRINT particles. Pharm Res 2008;25:2845-52.
42. Heidi MM, Yun-Seok R, Xiao W. Nanomedicines in pulmonary delivery. Int J Nano med 2009; 4:299-319.
43. Patil JS, Sarasija S. Physicochemical characterization, in-vitro release and permeation studies of respirable Rifampicin-cyclodextrin inclusion complexes. Indian J Pharm Sci 2009;71:638-43.
44. Zahoor A, Sharma S, Khuller GK. Inhaleable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298-303. (Pubitemid 41338657)
45. Justo OR, Moraes AM, Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment. J Pharm Pharmacol 2005;57:23-30. (Pubitemid 40030098)
46. Garcia-Contreras L, Marcol T, Bell SJD, Hickey AJ. Evaluation of novel particles aspulmonary delivery systems for insulin in rats. AAPS Pharm Sci 2003;5:9.
47. Brogden RN, Tavis D. Budesonide: An update review of its pharmacological properties, and therapeutic effcacy in asthma and rhinitis. Drugs 1992;44:375-407.
48. Falcoz C, Mackie A, McDowall J, McRae J. Yogendran L, Ventrsca G. Oral bioavailability of futicasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:459-60.
49. Neal MD, Majid RF. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003;255:175-87.